Clinical trial
Biological Therapy in Treating Patients at High-Risk or With Lymphoma…
NCT00002663 · Atara Biotherapeutics, Industry · Completed
Key facts
| NCT number | NCT00002663 |
|---|---|
| Title | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies |
| Official title | An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA… |
| Lead sponsor | Atara Biotherapeutics, Industry |
| Collaborators | Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma |
| Intervention type | Biological |
| Interventions | Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) |
| Enrollment | 58 |
| Start date | Mar 1, 1995 |
| Primary completion | Jul 1, 2019 |
| Completion | Jul 1, 2019 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 13, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: